Our top pick for
Avantor Inc is a specialty chemicals business based in the US. Avantor shares (AVTR) are listed on the NYSE and all prices are listed in US Dollars. Avantor employs 12,400 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$38.35|
|52-week range||$22.49 - $44.37|
|50-day moving average||$41.07|
|200-day moving average||$35.94|
|Wall St. target price||$43.42|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.45|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||-5.26%|
|1 month (2021-09-17)||-10.42%|
|3 months (2021-07-17)||5.88%|
|6 months (2021-04-16)||19.10%|
|1 year (2020-10-16)||56.79%|
|2 years (2019-10-17)||174.71%|
|3 years (2018-10-14)||N/A|
|5 years (2016-10-14)||N/A|
Valuing Avantor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avantor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avantor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, Avantor shares trade at around 85x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Avantor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 billion.
The EBITDA is a measure of a Avantor's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$7 billion|
|Operating margin TTM||13.63%|
|Gross profit TTM||$2.1 billion|
|Return on assets TTM||5.68%|
|Return on equity TTM||11.98%|
|Market capitalisation||$23.3 billion|
TTM: trailing 12 months
There are currently 16.4 million Avantor shares held short by investors – that's known as Avantor's "short interest". This figure is 8.6% down from 18.0 million last month.
There are a few different ways that this level of interest in shorting Avantor shares can be evaluated.
Avantor's "short interest ratio" (SIR) is the quantity of Avantor shares currently shorted divided by the average quantity of Avantor shares traded daily (recently around 4.8 million). Avantor's SIR currently stands at 3.43. In other words for every 100,000 Avantor shares traded daily on the market, roughly 3430 shares are currently held short.
However Avantor's short interest can also be evaluated against the total number of Avantor shares, or, against the total number of tradable Avantor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avantor's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Avantor shares in existence, roughly 30 shares are currently held short) or 0.0283% of the tradable shares (for every 100,000 tradable Avantor shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avantor.
Find out more about how you can short Avantor stock.
We're not expecting Avantor to pay a dividend over the next 12 months.
Over the last 12 months, Avantor's shares have ranged in value from as little as $22.49 up to $44.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Avantor's is 1.6868. This would suggest that Avantor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.